At the Heart of
Cardiac Innovation

Shaping the Future of TR Care
with Patient-centric Solutions

About Innoventric

Since its foundation, Innoventric has been committed to addressing the complexities of tricuspid regurgitation
with our transcatheter TR solutions. As leaders in cross-caval technologies, we are dedicated to the ongoing
development of advanced devices to extend the reach of TR treatment. Our approach is rigorously data-driven,
with its roots grounded deep in clinical research. We possess a robust patent portfolio in cross-caval technologies
and are devoted to continuous improvement to enhance patient care for those with structural heart disease. Our
treatments are designed to benefit a broad spectrum of patients, with the aim of making high-quality care more
accessible and improving health outcomes.

Management Team

Amir Danino

Founder and CEO

The founder and CEO of Innoventric and the inventor of the company’s technology. Amir has 18 years of experience in the medical device field, mainly in structural interventional cardiology, bringing aortic, mitral, and tricuspid valve projects from concept to clinical application.
Amir served on some of the most exciting structural heart projects and has broad experience in R&D, clinical affairs, regulatory affairs, and business development.
Amir is a prolific inventor of medical device technologies, with more than 20 granted cardiovascular and orthopedic patents and many more pending.
Amir holds a B.Sc. in Biomedical Engineering from Ben-Gurion University and an M.Sc. in Mechanical Engineering from Tel-Aviv University.
In his free time, Amir loves drumming and is also an enthusiastic hiker—he has walked the Israeli National Trail twice!

Rafi Benary

Rafi Benary is an experienced medical device entrepreneur with over 25 years in the field of cardiovascular medical devices. Over the last two decades, Rafi has founded several leading medical device companies and was the founding CEO of Ventor Technologies, a TAVR device manufacturer, which was acquired by Medtronic in early 2009.
Rafi earned his B.E. and M.Sc. in mechanical engineering and Materials Science from Stony Brook University (NY).
Rafi is an artisan blade and knife maker, skilled in identifying raw elements and transforming them into masterpieces.

David Planer

Dr. Planer is the head of interventional cardiology at Hadassah MC. He holds extensive experience in coronaries, structural heart disease, and endovascular interventions which was acquired at leading cardiac centers such as Columbia University Medical Center and Hadassah Medical Center.
Dr. Planer has vast experience in medical device development, gathered by working on numerous medical devices and projects. Dr. Planer is an expert in maturing early-stage technology from pre-clinical work through FIH studies to proctoring physicians.
David voluntarily practices medicine outside of the hospital for the benefit of his community and country. With the little time left, David enjoys training and physical activity.

Einat Har

Einat is Innoventric’s Chief Financial Officer. She is responsible for providing the legal and financial infrastructure for all operations and does so with great talent.
Einat has over 30 years of experience in financial and legal roles for technology companies, large global firms, and Venture Capitals.
Einat holds a degree in Economics and Accounting from Tel Aviv University, an Executive MBA from Bradford University, and is certified as a Mediator by the Israeli Tel Aviv court. She brings our team a perfect blend of financial know-how and legal expertise.
Outside of work, Einat loves giving back. She actively mentors aspiring female CFOs and helps teenagers dip their toes into the entrepreneurial world. When she's not busy, you can find her hitting the gym for functional training or hiking.

Chen Lereya

Head of Clinical Operations

Chen is the driving force behind the clinical operations at Innoventric, running multiple clinical evaluations for multiple products across the globe and pushing our clinical work plan forward with unwavering dedication.
With her B.Sc. in Biomedical Engineering from Ben-Gurion University and 15 years of project management and clinical trial management experience, Chen has been instrumental to Innoventric’s growth and success since its inception.
Chen is an avid runner and swimmer, making her accustomed to long-distance efforts.

Yair Pichersky

Yair has a natural curiosity for engineering and a huge talent for medical device Research and Development, which he brings to his role as Head of R&D.
In his 10 years of experience in cardiovascular medical devices and over 6 years at Innoventric, he has brought several medical devices from concept to realization with great ingenuity.
Yair is an expert on taking a clinical need and providing it with a mechanical solution that meets the R&D, V&V, and QA requirements. In his position, Yair constantly leads such efforts with great leadership.
Yair holds a B.Sc. in Mechanical Engineering from Ben Gurion University.
Apart from his work, Yair is a passionate sailor.

Eyal Kislev

Head of Engineering

Eyal is a true perfectionist with unparalleled attention to detail and an in-depth understanding of complex processes. With his experience as an R&D project manager, he has the ultimate background for overseeing the engineering and manufacturing processes.
In addition to leading the Engineering and manufacturing at Innoventric, Eyal led some of the most interesting R&D and V&V projects, demonstrating exceptional project management skills.
Eyal holds a B.Sc. in Mechanical Engineering from Afeka College and is currently pursuing his M.Sc. in Systems Engineering at Tel-Aviv University.
Outside of work, Eyal enjoys hiking and traveling to new places.

Adi Avisira

QA & Project Engineer

With a B.Sc. in Medical Engineering from Afeka College, Adi became a master of her niche, blending technical know-how with a passion for ensuring top-notch quality control.
Over the past three years, Adi has been deeply involved in the development of various products and the ongoing management of the company's quality system.
Outside of work, she is a passionate basketball fan who never misses a game of her favorite team.

Tami Kohn

External Relations Manager

Tami brings a unique blend of expertise to Innoventric. Holding a B.Sc. in Biomedical Engineering and an Executive MBA from Ben Gurion University, Tami combines technical knowledge with business insight.
With over a decade of experience in R&D project management and customer-facing roles, Tami has developed her ability to communicate effectively, gain trust, establish long-term relationships, and amplify brand presence.
Outside of work, she enjoys functional training and family trips.

Michal Krieger

Office and Administrative Manager

With over 20 years of administrative management experience in multinational corporations, Michal brings invaluable expertise to Innoventric. She ensures seamless workspace operations, optimizes efficiency, and fosters productivity. In former positions, Michal played pivotal procurement and global office support roles. Holding two B.A.s, one in Sociology and Anthropology from Bar-Ilan University and the second in Learning Disabilities Education from the Open University, Michal deeply understands organizational dynamics.
She is known for her meticulous attention to detail and strong work ethic.
Outside of work, Michal enjoys jogging, family quality time, crafting, and collecting vintage items.

Scientific Advisory Board

Dr. Chet Rihal

Dr. Rihal graduated from the University of Manitoba Medical School and completed his post graduate training at Mayo Clinic. Following his first faculty position at McMaster University he returned to Mayo in 1995, where he has served in several leadership roles including directing the cardiac catheterization laboratory and chairing the Department of Cardiovascular Medicine.
Dr. Rihal’s focuses his clinical and research interests in Structural Heart Disease and has pioneered novel procedures such as paravalvular leak closure, transvenous transseptal mitral valve in valve, and a variety of TMVR and TTVR devices. He has participated in early stage and pivotal trials of novel technologies such as TAVR and edge to edge repair. Dr. Rihal has accompanied and assisted Innoventric since the company inception.

Dr. Stefan Verheye

Dr. Stefan Verheye, MD, PhD, has been a senior interventional cardiologist at the Antwerp Cardiovascular Center, Antwerp Belgium since 2000. He is a member of the European Association of Percutaneous Cardiovascular Interventions, a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Clinical Professor Interventional Cardiology at the University of Brussels. He serves as a member of Scientific Advisory Board of several medical device manufacturers. Dr. Verheye is the author of over 150 peer-reviewed journals (www.pubmed.com), ten book chapters, over 400 abstracts, and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary artery disease, structural heart disease, heart failure). He has presented at numerous major conferences such as TCT (Transcatheter Cardiovascular Therapeutics), EuroPCR (European Percutaneous Course on Revascularization), AsiaPCR, AHA (American Heart Association), ACC (American College of Cardiology) and ESC (European Society of Cardiology) and has directed and transmitted several coronary and structural live cases to TCT, EuroPCR and ESC. He served as the medical director for V-Wave, Israel, a medical device company, developing and manufacturing inter-atrial shunt for heart failure. His entrepreneurial interests led to the co-foundation of Hilbert Paradox, NV, a start-up company encompassing a unique way of capturing and correlating digital health data, applying data- and knowledge engineering, which was later on acquired by a large CRO. He co-founded ainthoven, NV, a start-up company dedicated to on-line cardiac signal analytics by exploring the hyperspace of learning algorithms, and recently co-founded Amynas, BV a Belgian based, incorporated technology platform company specializing in nanofiber electrospinning providing anti-infective and anti-inflammatory protection for implanted devices, including CIEDs, neuro-stimulatory and orthopedic devices.
Stefan Verheye graduated from the School of Medicine at the University of Leuven in Belgium and was a resident internal medicine and cardiology both at the University of Aachen, Germany and OLV-Hospital, Aalst, Belgium. After a 2-year fellowship interventional cardiology in Aalst, Belgium, he completed a 2-year period as a research associate and visiting interventional cardiologist at the Andreas Gruentzig Cardiovascular Center at Emory University School of Medicine in Atlanta, Georgia, and served as an affiliate scientist, Division of Molecular Medicine for Yerkes Regional Primate Research Center of Emory University. He earned his PhD at the Department of Pharmaceutical Sciences of the University of Antwerp.

Dr. Philipp Lurz

Professor Dr. Philipp C. Lurz, MD, PhD, serves as the Director of the Department of Cardiology at the University Mainz, Germany. He earned his medical degree and completed his PhD at University College London, where he conducted research at the Institute of Child Health and the Great Ormond Street Hospital for Children, as well as The Heart Hospital in London. Following this, he served as the deputy head of Cardiology at the Heart Center Leipzig before assuming his current position in Mainz.
Dr. Lurz is broadly recognized as an interventional cardiologist with extensive clinical and scientific expertise in congenital structural disease, valvular heart disease, and heart failure. He has received multiple accolades such as the Thomas J. Linnemeier Award at TCT 2018 and the Albert-Fraenkel award of the German Heart Association. His primary research focus lies in structural heart disease and Heart Failure with Preserved Ejection Fraction.

Dr. Bill Abraham

Dr. Abraham earned his medical degree from Harvard Medical School, following which he completed his residency in Internal Medicine and fellowships in Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of Colorado. He previously held leadership positions at the University of Colorado, the University of Cincinnati, the University of Kentucky, and the Ohio State University. At Ohio State, Dr. Abraham held several leadership positions, including an Associate Dean position, managing the College of Medicine’s non-cancer clinical and translational research portfolio. As Division Director from October 2002 until January 2019, Dr. Abraham developed one of the largest and most successful academic programs of Cardiovascular Medicine in the U.S. As a noted heart failure specialist, Dr. Abraham has been recognized as one of the “Best Doctors in America” for 20 consecutive years and has been ranked among the top 10% of physicians nationally in patient satisfaction. Dr. Abraham is recognized as an international leader in heart failure research. His research has contributed to the approval/adoption of several new therapies for heart failure, including beta-blockers, natriuretic peptides, ultrafiltration, cardiac resynchronization therapy, implantable hemodynamic monitoring devices, transvenous phrenic nerve stimulation, cardiac contractility modulation, baroreflex activation therapy, and transcatheter mitral valve repair. Dr. Abraham has authored over 1,500 original papers, abstracts, book chapters, and review articles. He serves as series editor for the "Color Atlas and Synopsis of Cardiovascular Medicine." He has been named to the Clarivate Analytics Highly Cited Researchers list, ranking him among the top 1% most cited researchers for his subject field, and recognized as one of The World’s Most Influential Scientific Minds. In 2017, Dr. Abraham was the recipient of the American College of Cardiology Distinguished Scientist Award. In 2022, Dr. Abraham received the Pioneer Award from the Heart Failure Society of America. In addition to his clinical and scholarly activities, Dr. Abraham serves as chief medical officer at V-Wave and as a consultant to companies involved in new drug and device development for heart failure.

Clinical Collaborations